AlpenGlobal Capital LLC Purchases New Shares in Stryker Corporation $SYK

AlpenGlobal Capital LLC purchased a new position in shares of Stryker Corporation (NYSE:SYK) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,944 shares of the medical technology company’s stock, valued at approximately $1,953,000. Stryker comprises approximately 1.3% of AlpenGlobal Capital LLC’s investment portfolio, making the stock its 25th biggest holding.

A number of other institutional investors have also added to or reduced their stakes in SYK. Brighton Jones LLC lifted its holdings in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after acquiring an additional 609 shares during the period. Schnieders Capital Management LLC. bought a new position in Stryker in the 2nd quarter valued at $205,000. Marshall Wace LLP grew its stake in Stryker by 107.9% in the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after purchasing an additional 77,831 shares during the period. Nebula Research & Development LLC purchased a new stake in shares of Stryker during the 2nd quarter valued at $219,000. Finally, HUB Investment Partners LLC bought a new stake in shares of Stryker during the 2nd quarter worth $253,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Up 0.8%

Stryker stock opened at $329.86 on Friday. The firm has a 50 day simple moving average of $310.12 and a 200 day simple moving average of $337.97. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87. The firm has a market capitalization of $126.46 billion, a price-to-earnings ratio of 38.18, a P/E/G ratio of 2.10 and a beta of 0.77.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter in the prior year, the company earned $2.84 EPS. The company’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, analysts predict that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is 40.74%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on SYK shares. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a report on Friday, May 1st. The Goldman Sachs Group restated a “neutral” rating and set a $361.00 price objective on shares of Stryker in a report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 target price on shares of Stryker in a research note on Friday, May 1st. Robert W. Baird set a $385.00 target price on shares of Stryker in a research report on Friday, May 1st. Finally, BTIG Research decreased their price target on shares of Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research note on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $392.87.

Insider Buying and Selling

In other Stryker news, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the transaction, the vice president owned 177 shares in the company, valued at $50,170.65. This trade represents a 95.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 323,264 shares of company stock valued at $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.